Pabal, Duratocin
Evidence Grade B — Strong clinical evidence. 403 published studies, 243 human. 96 registered clinical trials.
Carbetocin is a long-acting version of oxytocin that has been studied to prevent dangerous bleeding after childbirth. It is registered in over 80 countries outside the US but has never received FDA approval. A heat-stable formulation — one that does not need refrigeration — was added to the WHO Essential Medicines List, addressing a critical need in tropical and low-resource settings where standard oxytocin degrades in the heat.
403 published studies: 243 human, 72 animal, 17 in-vitro, 73 reviews
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019.
The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Carbetocin activates the same oxytocin receptor as natural oxytocin, producing uterine contractions. Its molecular structure includes a modification that prevents the body from breaking it down as quickly as natural oxytocin, extending its duration of action to approximately 40 minutes compared to oxytocin's 3–17 minutes. This longer action means a single dose may be sufficient where oxytocin would require a continuous infusion.
The WHO-sponsored CHAMPION trial (over 29,000 women) found heat-stable carbetocin non-inferior to oxytocin for preventing postpartum haemorrhage after vaginal delivery. This matters because standard oxytocin requires refrigeration, which is often unreliable in the regions where postpartum haemorrhage is the leading cause of maternal death. The US market has not been pursued, likely because reliable cold-chain oxytocin is ubiquitous in US healthcare facilities. A development programme for Prader-Willi syndrome (a genetic condition) failed, closing the most advanced pathway for major-market development. Carbetocin's global health significance rests on the heat-stable formulation for resource-limited settings.
Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention
Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone
Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery
Health Canada Market Authorisation
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
